Home

Who we are?

ImmuNovo is a private biotechnology company, with headquarters in ‘s-Hertogenbosch (The Netherlands), that is engaged in the discovery and development of immune therapeutics in the field of oncology. In particular, the focus of ImmuNovo’s research is on therapeutic vaccines based on synthetic peptide antigens (Sclerostin, PD-1, Gastrine, VEGF and GnRH) for which the company has a unique technology platform. Read more »


What we do

ImmuNovo is committed to being at the forefront of research and development in therapeutic vaccines utilizing its peptide technology and its adjuvant technology. ImmuNovo has received and continues to add to a broad portfolio of patents for its proprietary technologies and compounds. ImmuNovo’s’ commercial strategy is to establish strong cohesive relationships with major participants in the immunotherapy market as a result of its multi-indication and multi-platform technology. Read more »

News

---

Immunovo joins BIO 2013   Immunovo was there! On the BIO International Convention, end of april in Chicago, the largest global event for the biotechnology industry. The BIO attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry. The results of BIO 2013: more than 130.000 partnering requests, 25,500+ meetings and 4,900 exhibitor partnering meetings. One-on-one partnering exceeds all industry records. Read more Bacillus Calmette–Guerin (BCG) immunotherapy for bladder cancer   Since the first report in 1976, the accumulated clinical evidence supports the use of intravesical BCG therapy as one of the standard methods of managing intermediate- and high-risk NMIBC. Although the precise immunological mechanism of BCG therapy is still unclear, our understanding is increasing of reactions induced by BCG complexes, including infection of urothelial cells or bladder cancer cells, induction of immune responses, and induction of antitumor effects. A number of clinical and preclinical studies have been conducted to overcome the limitations of intravesical BCG therapy. Among them, development of a non-live bacterial agent is one of the most promising candidates for a future substitute for live BCG. Read more. Data GLOBOCAN 2008   Cancer is the leading cause of death in economically developed countries and the second leading cause of death in developing countries. The global burden of cancer continues to increase largely because of the aging and growth of the world population alongside an increasing adoption of cancer-causing behaviors, particularly smoking, in economically developing countries. These data is based on the GLOBOCAN 2008. Read more. Monoclonal Antibody Targets Kills Leukemia Cells   Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells. Read more. Joost van Bree, CEO Immunovo: 'This method can also be a valid approach for therapeutic vaccins.' All about immotherapy: CIMT 14-16 may, Mainz Germany   Europe's largest meeting focused on cancer immunotherapy research and development, CIMT 14-16 may in Mainz Germany. Read more about the program Mouse study sheds light on why some cancer vaccines fail   A typical therapeutic vaccine against cancer contains a cancer-specific peptide, or protein fragment, that is injected under a patient's skin. The peptide serves as a red flag for the immune system. If all goes well, the patient's immune system recognizes the peptide as something to be attacked and boosts the population of cancer-fighting T-cells in the bloodstream. A recent study in mice suggests that changing a traditional ingredient (water instead of oil) in the vaccines could make a big difference. Read more. Welcome to the new ImmuNovo website   This website tells you everything you need to know about ImmunoNovo and especially about the development of our therapeutic vaccines. Besides you can also find here (inter)national news on immunotherapy, a regular fresh update of the developments within ImmuNovo and the opportunity for subscription on our newsletter. Read more » Specialized in peptide technology and its adjuvant technology   Immunotherapy is a rapidly emerging field providing new therapies for cancer and incurable diseases. According to Immunovo’s CEO dr. Joost van Bree a major attraction of this approach is that it offers the prospect of precisely aimed therapies with greatly reduced risk of side effects and minimal discomfort for the patient. Read more about Immunovo’s save and effective adjuvants and strong relationships. Read more » ImmuNovo will make a major contribution to in-depth research and solutions   Prof. Dr. Bob Pinedo MD PhD is linked to ImmuNovo as a Senior Medical and Scientific Advisor. Being a acknowledged oncologist Mr Pinedo has confidence in the future of immunotherapy and hence in the vision and policy of ImmuNovo. Read more »